Sage Journals: Discover world-class research

Abstract

Background

Cancer may influence the risk of thromboembolism and bleeding associated with the CHA₂DS₂-VASc score. We examined the risk of thromboembolism and bleeding associated with the CHA₂DS₂-VASc score in atrial fibrillation patients with and without recent cancer.

Methods and results

Using nationwide registers all patients diagnosed with atrial fibrillation from 2000 to 2015 and not on oral anticoagulation or heparin therapy were included and followed for 2 years. Recent cancer was defined by a cancer diagnosis 5 years or fewer earlier. Risks of thromboembolism and bleeding were estimated in cumulative incidence curves and Cox regression models. We included 122,053 patients with incident atrial fibrillation, 12,014 (10%) had recent cancer. The 2-year cumulative incidence of thromboembolism and bleeding in patients with versus without recent cancer was 1.7% (95% confidence interval (CI) 0.5–2.8) and 4.3% (95% CI 2.4–6.2) versus 1.2% (95% CI 0.9–1.5) and 1.7% (95% CI 1.4–2.0) for CHA₂DS₂-VASc score 0; 3.2% (95%CI 2.2-4.3) and 4.4% (95%CI 3.2-5.6) versus 1.8% (95%CI 1.6-2.1) and 3.0% (95% CI 2.7–3.3) for CHA₂DS₂-VASc score 1; and 7.1% (95% CI 6.6–7.7) and 6.8% (95% CI 6.3–7.2) versus 10.9% (95% CI 10.7–11.1) and 6.2% (95% CI 6.1–6.4) for CHA₂DS₂-VASc score 2 or greater. Although the CHA₂DS₂-VASc score was associated with thromboembolism and bleeding in both patients with and without cancer, the association differed between the groups for thromboembolism (test for interaction, p < 0.001) and bleeding (test for interaction, p < 0.001).

Conclusion

The association of the CHA₂DS₂-VASc score and risk of thromboembolism and bleeding differed between atrial fibrillation patients with and without recent cancer. Therefore, the CHA₂DS₂-VASc score should be used with caution in patients with recent cancer.

Keywords

Atrial fibrillation cancer thromboembolic risk stroke bleeding risk

Get full access to this article

View all access options for this article.

References

Bang

Seok

Kim

et al.

Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol 2011; 7: 53–53.

Kim

Hong

Kim

et al.

Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke 2010; 41: 798–801.

Rogers

. Cerebrovascular complications in cancer patients. Neurol Clin 2003; 21: 167–192.

January

Wann

Alpert

et al.

2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014; 64: e1–e76.

Kirchhof

Benussi

Kotecha

et al.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–2962.

Liu

Chang

et al.

Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 2013; 165: 355–357.

Schmidt

SAJ

Sandegaard

et al.

The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449–490.

Rix

Riahi

Overvad

et al.

Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012; 46: 149–153.

Krarup

L-H

Boysen

Janjua

et al.

Validity of stroke diagnoses in a national register of patients. Neuroepidemiology 2007; 28: 150–154.

10.

Wallach Kildemoes

Toft Sorensen

Hallas

. The Danish National Prescription Registry. Scand J Public Health 2011; 39: 38–41.

11.

Olesen

Lip

GYH

Hansen

et al.

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124–d124.

12.

Lip

Nieuwlaat

Pisters

et al.

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest J 2010; 137: 263–272.

13.

Andersen

Geskus

de Witte

et al.

Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012; 41: 861–870.

14.

R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (accessed 6 February 2018).

15.

Nielsen

Skjoeth

Overvad

et al.

Female sex is a risk modifier – not a risk factor – for stroke risk assessment in atrial fibrillation: using a CHA2DS2-VA score rather than CHA2DS2-VASc. Eur Heart J 2017; 38: ehx493.5768-ehx493.5768–ehx493.5768-ehx493.5768.

16.

Ording

Horváth-Puhó

Adelborg

et al.

Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 2017; 6: 1165–1172.

17.

Nilsson

Holmberg

Garmo

et al.

Increased incidence of stroke in women with breast cancer. Eur J Cancer 2005; 41: 423–429.

18.

Zhang

Y-Y

Chan

DKY

Cordato

et al.

Stroke risk factor, pattern and outcome in patients with cancer. Acta Neurol Scand 2006; 114: 378–383.

19.

Grisold

Oberndorfer

Struhal

. Stroke and cancer: a review. Acta Neurol Scand 2009; 119: 1–16.

20.

Kamphuisen

Beyer-Westendorf

. Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res 2014; 133(Suppl 2): S49–S55.

21.

Decousus

Tapson

Bergmann

J-F

et al.

Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 69–79.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.95 MB

CHA 2 DS 2 -VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer

Abstract

Background

Methods and results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material